The global ovarian cancer diagnostics market accounted for USD 1.55 billion in 2023 and is expected to reach at USD 3.16 billion by 2034 with a CAGR of 6.68% during the forecast period 2024-2034. Rising prevalence of ovarian cancer, increasing focus on early detection & treatment, growing governments initiatives, surge in funding for research into ovarian cancer, rising healthcare spending, increasing advancements in technology, growing activity in research & development, surge in the approval of new diagnostic products and increasing introduction of innovative diagnostic devices for ovarian cancer are some of the key factors boosting the market growth.
Surge in the approval of new diagnostic products is predicted to boost the market growth during the forecast period. Ovarian cancer, which develops in the ovaries, encompasses various types, with epithelial ovarian cancer being the most prevalent. Uncontrolled cell growth in ovarian tissue is the main factor contributing to this cancer, making it a leading cause of female mortality globally. The demand for precise and timely ovarian cancer diagnostics is growing. Consequently, industry participants are concentrating on the creation and introduction of innovative diagnostic solutions. For instance, in January 2023, The OverC Multi-Cancer Detection Blood Test (MCDBT) has been granted a breakthrough device designation by the FDA. This test is specifically developed for early detection of various cancers. This test can identify cancers such as esophageal, liver, lung, ovarian, and pancreatic cancers in adults aged 50 to 75 who have an average risk.
By cancer type, epithelial tumors was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the increasing need for diagnostic tools & tests designed specifically for detecting epithelial tumors, particularly in ovarian cancer, growing advancements in diagnostic technologies are enhancing the accuracy and efficiency of identifying epithelial ovarian tumors, surge in number of patients diagnosed in advanced stages, and rising regulatory approvals for relevant diagnostic methods. For instance, in November 2022, Roche has revealed that the FDA has given its approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This marks a significant milestone as it becomes the inaugural immunohistochemistry (IHC) companion diagnostic test authorized to assist in identifying patients with epithelial ovarian cancer (EOC). Additionally, germ cell tumor is predicted to grow at the fastest CAGR during the forecast period owing to the surge in number of women populations aged between 20 and 30 years suffering from germ cell tumor.
By diagnosis type, imaging was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the growing significance of early cancer detection & accurate staging, increased use of advanced imaging methods such as CT, MRI, & PET scans to identify metastasis & assess disease severity. Computed Tomography (CT) is gaining popularity due to its enhanced sensitivity, and there is a rise in approvals from regulatory agencies for these techniques. Additionally, blood tests is predicted to grow at the fastest CAGR during the forecast period owing to the rising technological advancements, growing consumer awareness, increased focus on genetic counselling & testing, and surge in developments in diagnostic tools. For instance, in October 2023, CpG Diagnostics Inc. is moving forward with the development of OvaPrintTM as a novel diagnostic tool for ovarian cancer.
By end-user, hospital laboratories was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the rising influx of patients seeking cancer diagnosis, increasing consumer awareness, and investments in healthcare infrastructure. Additionally, research institutes is predicted to grow at the fastest CAGR during the forecast period owing to rise in funding allocated for cancer research, and increased focus on developing innovative test products. For instance, in January 2024, Researchers at the Georgia Tech Integrated Cancer Research Center (ICRC) have integrated machine learning with data on blood metabolites to create a novel test capable of identifying ovarian cancer with 93 percent accuracy in samples from their research cohort.
North America region is anticipated for the highest revenue share during the forecast period owing to the positive governmental actions, higher healthcare spending, the presence of major manufacturers, rising prevalence of ovarian cancer, growing approvals for advanced diagnostics, and surge in mergers & acquisitions among industry participants. For instance, in January 2023, It has been announced that Agilent Technologies Inc. has acquired Avida Biomed, a young life sciences company that specializes in sophisticated target enrichment procedures. These processes offer unique features intended for clinical researchers studying cancer with next-generation sequencing (NGS) methods. This acquisition bolsters Agilent's renowned SureSelect portfolio and aligns with its strategic objective of broadening its presence in the rapidly evolving realms of clinical research and diagnostics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhancements in healthcare infrastructure, surge in consumer awareness, rising demand for early disease detection, and increasing number of new product launches. For instance, in May 2022, Inex Innovate introduced the OvaCis Rapid test for ovarian cancer detection in markets across Southeast Asia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in the approval of new diagnostic products is predicted to boost the market growth during the forecast period. Ovarian cancer, which develops in the ovaries, encompasses various types, with epithelial ovarian cancer being the most prevalent. Uncontrolled cell growth in ovarian tissue is the main factor contributing to this cancer, making it a leading cause of female mortality globally. The demand for precise and timely ovarian cancer diagnostics is growing. Consequently, industry participants are concentrating on the creation and introduction of innovative diagnostic solutions. For instance, in January 2023, The OverC Multi-Cancer Detection Blood Test (MCDBT) has been granted a breakthrough device designation by the FDA. This test is specifically developed for early detection of various cancers. This test can identify cancers such as esophageal, liver, lung, ovarian, and pancreatic cancers in adults aged 50 to 75 who have an average risk.
By cancer type, epithelial tumors was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the increasing need for diagnostic tools & tests designed specifically for detecting epithelial tumors, particularly in ovarian cancer, growing advancements in diagnostic technologies are enhancing the accuracy and efficiency of identifying epithelial ovarian tumors, surge in number of patients diagnosed in advanced stages, and rising regulatory approvals for relevant diagnostic methods. For instance, in November 2022, Roche has revealed that the FDA has given its approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This marks a significant milestone as it becomes the inaugural immunohistochemistry (IHC) companion diagnostic test authorized to assist in identifying patients with epithelial ovarian cancer (EOC). Additionally, germ cell tumor is predicted to grow at the fastest CAGR during the forecast period owing to the surge in number of women populations aged between 20 and 30 years suffering from germ cell tumor.
By diagnosis type, imaging was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the growing significance of early cancer detection & accurate staging, increased use of advanced imaging methods such as CT, MRI, & PET scans to identify metastasis & assess disease severity. Computed Tomography (CT) is gaining popularity due to its enhanced sensitivity, and there is a rise in approvals from regulatory agencies for these techniques. Additionally, blood tests is predicted to grow at the fastest CAGR during the forecast period owing to the rising technological advancements, growing consumer awareness, increased focus on genetic counselling & testing, and surge in developments in diagnostic tools. For instance, in October 2023, CpG Diagnostics Inc. is moving forward with the development of OvaPrintTM as a novel diagnostic tool for ovarian cancer.
By end-user, hospital laboratories was the highest revenue-grossing segment in the global ovarian cancer diagnostics market in 2023 owing to the rising influx of patients seeking cancer diagnosis, increasing consumer awareness, and investments in healthcare infrastructure. Additionally, research institutes is predicted to grow at the fastest CAGR during the forecast period owing to rise in funding allocated for cancer research, and increased focus on developing innovative test products. For instance, in January 2024, Researchers at the Georgia Tech Integrated Cancer Research Center (ICRC) have integrated machine learning with data on blood metabolites to create a novel test capable of identifying ovarian cancer with 93 percent accuracy in samples from their research cohort.
North America region is anticipated for the highest revenue share during the forecast period owing to the positive governmental actions, higher healthcare spending, the presence of major manufacturers, rising prevalence of ovarian cancer, growing approvals for advanced diagnostics, and surge in mergers & acquisitions among industry participants. For instance, in January 2023, It has been announced that Agilent Technologies Inc. has acquired Avida Biomed, a young life sciences company that specializes in sophisticated target enrichment procedures. These processes offer unique features intended for clinical researchers studying cancer with next-generation sequencing (NGS) methods. This acquisition bolsters Agilent's renowned SureSelect portfolio and aligns with its strategic objective of broadening its presence in the rapidly evolving realms of clinical research and diagnostics. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the enhancements in healthcare infrastructure, surge in consumer awareness, rising demand for early disease detection, and increasing number of new product launches. For instance, in May 2022, Inex Innovate introduced the OvaCis Rapid test for ovarian cancer detection in markets across Southeast Asia.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Cancer Type, Diagnosis Type, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Ovarian Cancer Diagnostics Market Report 2023 - 2034
Ovarian Cancer Diagnostics Market Analysis & Forecast by Cancer Type 2023 - 2034 (Revenue USD Bn)
- Stromal Cell Tumor
- Germ Cell Tumor
- Epithelial Tumor
- Others
Ovarian Cancer Diagnostics Market Analysis & Forecast by Diagnosis Type 2023 - 2034 (Revenue USD Bn)
- Blood Test
- KRAS Mutation
- ER & PR
- CA125
- BRCA
- HER2
- CEA
- Others
- Imaging
- Ultrasound
- PET Scan
- MRI Scan
- CT Scan
- Others
- Biopsy
- Others
Ovarian Cancer Diagnostics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Research Institutes
- Hospital Laboratories
- Cancer Diagnostic Centers
- Others
Ovarian Cancer Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Ovarian Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
8. Ovarian Cancer Diagnostics Market: Diagnosis Type Estimates & Trend Analysis
9. Ovarian Cancer Diagnostics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Ovarian Cancer Diagnostics Market
12. Europe Global Ovarian Cancer Diagnostics Market
13. Asia Pacific Global Ovarian Cancer Diagnostics Market
14. Latin America Global Ovarian Cancer Diagnostics Market
15. MEA Global Ovarian Cancer Diagnostics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- AstraZeneca plc
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific
- Johnson & Johnson Services Inc
- Abbott
- Siemens Healthcare GmbH
- Bio-Rad Technologies Inc
- GlaxoSmithKline plc
- Quest Diagnostics Incorporated
